HealthMine and Pulse8 recently hosted a free Mid-Year Stars Strategy webinar to help Medicare plans effectively prepare for the end of the measurement year. This webinar includes exclusive insights to shift your strategy and improve CAHPS from Melissa Smith, EVP of Consulting and Professional Services at HealthMine; Kent Holdcroft, EVP of Growth at HealthMine; and Marge Ciancetta, Senior Business Analyst at Pulse8. The conversation concludes with a valuable question and answer session that addresses concerns about the current known and proposed Star Ratings program changes.
To watch the replay, click here.
Bind Benefits announced that its personalized health plan will be offered on a fully insured basis to Georgia employers with more than 50 employees. With Bind, employers have the opportunity to lower healthcare costs while giving their employees a rich, affordable benefit with a broad network and more health care decision-making control.
Georgia has poor conditions for healthcare costs, access and outcomes, according to a 2020 report. The Peach State ranked last in WalletHub’s analysis of the best and worst states for health care.
“Bind removes the guesswork and complexity of healthcare cost and coverage, replacing it with certainty that your needs are covered and confidence in how much it will cost,” said Shawn Wagoner, Bind Chief Revenue Officer. “With this peace of mind, Bind members can focus on what matters most.”
Atlanta-based health insurance broker with USI Insurance Services, Jeff Gentry, values the choice and cost certainty Bind provides via its app and website. “With Bind, employees can search for their condition and see the different treatment options and providers available to them – with exact prices – so they can make more informed decisions and choose higher-value options. And Bind has made it so there is no compromise between cost and quality—high-quality treatments and providers cost less. That’s a win for employees and employers,” said Gentry.
Emulate Inc. this week announced the appointment of Scott D. Kantor as Chief Financial Officer. Reporting to Jim Corbett, Chief Executive Officer, Scott will be responsible for strengthening the organization’s operational readiness to meet the growing demand for organ-on-a-chip technology.
“Next-generation in vitro models by Emulate have the potential to transform drug discovery and development by replacing outdated 2-dimensional (2D) cell culture methods and reducing animal testing that has poor clinical translation,” Scott said. “I am eager to join this world-class leadership team to drive the biological revolution Emulate technology can enable.”
To read more, click here.
Kiio announced the release of a new claims-based study with WEA Trust. The study demonstrates their on-demand, digital musculoskeletal (MSK) platform significantly cuts wasteful medical spend, unnecessary diagnostics, treatment, and utilization of pain management medications — including 56% reduction in medical spend and 87% reduction in the use of opioids to treat pain. This is their fourth claims-based study, proving Kiio’s ability to reduce medical and pharmaceutical claims related to chronic MSK pain.
To read more, click here.
Picture: akindo, Getty Images